U.S. Markets closed

Trius Therapeutics price target raised to $15 from $10 at Leerink

Leerink raised its price target for Trius Therapeutics (TSRX) shares to $15 citing Cubist's (CBST) offer for the company. Leerink believes the market is currently pricing the deal's CVR at around 11c, which it notes is significantly below its calculated current value of $1.20. The firm reiterates an Outperform rating on Trius.